Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Consensus Rating of “Hold” by Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been given a consensus rating of “Hold” by the seven brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $28.1429.

KMTS has been the topic of several research analyst reports. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. BTIG Research lifted their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 target price for the company.

Insider Transactions at Kestra Medical Technologies

In other news, insider Timothy P. Moran sold 8,759 shares of the stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.61, for a total transaction of $198,040.99. Following the transaction, the insider directly owned 68,725 shares in the company, valued at approximately $1,553,872.25. This represents a 11.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alfred J. Ford, Jr. sold 13,015 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $23.90, for a total value of $311,058.50. Following the transaction, the insider directly owned 105,839 shares in the company, valued at approximately $2,529,552.10. This represents a 10.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 238,164 shares of company stock worth $5,700,952. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at $31,000. Russell Investments Group Ltd. raised its position in Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the period. BNP Paribas Financial Markets lifted its stake in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Daiwa Securities Group Inc. bought a new stake in Kestra Medical Technologies in the fourth quarter worth $72,000. Finally, Brown Brothers Harriman & Co. boosted its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after buying an additional 656 shares during the period.

Kestra Medical Technologies Price Performance

Kestra Medical Technologies stock opened at $27.91 on Thursday. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -11.53 and a beta of 0.58. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The business has a 50-day simple moving average of $24.30 and a 200 day simple moving average of $22.76. Kestra Medical Technologies has a 52 week low of $15.42 and a 52 week high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, research analysts forecast that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.